The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Open accessAbstract
Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC.Methods We undertook the open-label, randomised phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain. Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed). We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 week cycles of standard intravenous chemotherapy of cisplatin 75 mg/m(2) on day 1 plus docetaxel (75 mg/m(2) on day 1) or gemcitabine (1250 mg/m(2) on days 1 and 8). Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2). The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We assessed safety in all patients who received study drug (≥ 1 dose). This study is registered with ClinicalTrials.gov, number NCT00446225.Findings Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled. One patient received treatment before randomisation and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive standard chemotherapy. The preplanned interim analysis showed that the study met its primary endpoint; enrolment was halted, and full evaluation of the results was recommended. At data cutoff (Jan 26, 2011), median PFS was 9·7 months (95% CI 8·4-12·3) in the erlotinib group, compared with 5·2 months (4·5-5·8) in the standard chemotherapy group (hazard ratio 0·37, 95% CI 0·25-0·54; p < 0·0001). Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anaemia (one [1%] vs three [4%]), and increased amino-transferase concentrations (two [2%] vs 0). Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy. One patient in the erlotinib group and two in the standard chemotherapy group died from treatment-related causes.Interpretation Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR tyrosine-kinase inhibitors.Funding Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Temática de Investigacion Cooperativa en Cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“have shown improved efficacy and tolerability compared with chemotherapy in numerous phase III trials”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [32]
In the citing paper
“In clinical trials, the incidence of all-grade liver injury due to different smallmolecule targeted drugs such as tyrosine kinase inhibitors is reportedly 5-55% [144-149].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [147]
In the citing paper
“Afterwards, studies revealed that the reduced sensitivity to gefitinib or erlotinib in NSCLC was linked to EGFR-specific activating mutations.112–116”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [116]
In the citing paper
“The third-generation EGFR-TKIs include the WZ4002, CO-1686, AZD9291 and HM61713 inhibitors, which have demonstrated tumour responses in >50% of patients with the EGFR T790M mutation.8–12”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [9]
In the citing paper
“Eight randomised controlled phase III trials (table 1) have demonstrated that first-generation or second-generation EGFR-TKIs represent the best first-line treatment option in patients with advanced NSCLC whose tumours harbour EGFR mutations, when compared with chemotherapy, because they significantly improved the RR and progression-free survival (PFS).4–11”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [9]
In the citing paper
“Unfortunately, whilst patients with EGFRm+ tumors typically show good initial responses to first generation TKIs, most patients who respond to therapy ultimately develop disease progression after about 9-14 months of treatment (7-11).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [10]
In the citing paper
“Across clinical trials of first-line targeted therapy for oncogene-addicted subgroups of NSCLC, rates of objective response [G] typically range between 50% and 83% and complete responses [G] are rare; in addition, some patients exhibit de novo resistance16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [18]
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [18]
In the citing paper
“The magnitude of the improvement in progression-free survival observed in the current study is similar to that observed in studies of EGFR-mutation-positive tumors treated with firstline EGFR tyrosine kinase inhibitors.[24][25][26]”
From First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer (2014) · cites this paper as [25]
In the citing paper
“EGFR exon 19 deletions and EGFR exon 21 L858R represent the vast majority of EGFR activating mutations, and are exquisitely sensitive to approved EGFR TKIs such as erlotinib, gefitinib, and afatinib”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [2]
In the citing paper
“acquired resistance develops after a median of 9 to 13 months [2][3][4]”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [3]
In the citing paper
“Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations4–6.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [4]
In the citing paper
“Patients with classical EGFR mutations (L858R or exon 19 deletions (Ex19del)) show marked improvements in clinical outcomes when treated with first-, second- or third-generation tyrosine kinase inhibitors (TKIs)4–6,11.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [4]
In the citing paper
“One potential limitation of the current diagnostic approach of testing only for common exon 19 and 21 mutations, as was done in the EURTAC or OPTIMAL studies, 4,5 is that such an approach might miss identifying a number of patients who could have some benefit from EGFR TKI treatment.”
From Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations (2016) · cites this paper as [5]
In the citing paper
“a strikingly long survival compared to median OS of 19–28 months with first- or second-generation EGFR TKIs[17–19].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [19]
In the citing paper
“Several randomized clinical trials have demonstrated that EGFR TKIs are more effective, as measured by response rate (RR) and progression free survival (PFS), than chemotherapy when used as initial systemic treatment for advanced EGFR mutant NSCLC (1, 4–9).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [4]
In the citing paper
“Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective clinical therapies for EGFR mutant advanced non small cell lung cancer (NSCLC) patients (1–4).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [4]
In the citing paper
“The extension of approval of Erlotinib for patients harboring EGFR mutations, in addition to the previous indication for unselected patients with NSCLC after at least one chemotherapeutic line, was obtained after the publication of two large phase III trials conducted in Asia [65] and Europe [66], providing the definitive demonstration of superiority of an EGFR TKI over standard first-line”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [66]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [8]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [7]
In the citing paper
“Resistance to conventional EGFR-TKIs develops after a median of 10 to 12 months and is most commonly mediated by an acquired mutation, T790M1-5.”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [3]
In the citing paper
“Several studies have consistently demonstrated that the EGFR TKIs (gefitinib, erlotinib and afatinib) produce higher RRs, longer PFS and improve QoL compared with standard platinum-based doublet chemotherapy in patients with good PS (PS 0-2), whose tumour harbours an activating (sensitising) EGFR mutation [105-112].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [112]
In the citing paper
“In one small study, there was a PFS benefit with erlotinib (9.7 v 5.2 months; HR, 0.37; 95% CI, 0.25 to 0.54; P < .001); OS had not been reached by the time of publication.29”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [29]
In the citing paper
“Since the publication of the ASCO 2009 guideline and the ASCO EGFR provisional clinical opinion,59 results from seven trials of first-line EGFR TKIs for patients with EGFR mutations have been published.11,13,29,31,34,36,40”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [29]
In the citing paper
“It is now well established that lung cancers harboring these EGFR mutations are highly responsive to single-agent EGFR inhibitors with RECIST response rates of ~55%–75% (Mok et al., 2009; Rosell et al., 2012; Sequist et al., 2013b).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Rosell et al., 2012
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Self-citation
Research works printed but not linked: 1
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA) version 13.0 (accessed Aug 2, 2010).
Cited by
Sorted by citations
Items 701–800 of 1,020
Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80
Self-citationKobayashi, Y., Azuma, K., Nagai, H., Kim, Y. H., Togashi, Y., Sesumi, Y., Chiba, M., Shimoji, M., Sato, K., Tomizawa, K., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0407 · Cited by 80
Hamblin, A. D., Wordsworth, S., Fermont, J. M., Page, S., Kaur, K., Camps, C., Kaisaki, P. J., Gupta, A., Talbot, D. C., Middleton, M. R., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002230 · Cited by 80
Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
Palechor-Ceron, N., Krawczyk, E., Dakic, A., Simić, V., Yuan, H., Blancato, J. K., Wang, W., Hubbard, F. A., Zheng, Y., Dan, H., et al. (2019) · Cells · doi:10.3390/cells8111327 · Cited by 80
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System
Truini, A., Alama, A., Bello, M. G. D., Coco, S., Vanni, I., Rijavec, E., Genova, C., Barletta, G., Biello, F., & Grossi, F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00242 · Cited by 80
Xia, G., Chen, W., Zhang, J., Shao, J., Zhang, Y., Huang, W., Zhang, L., Qi, W., Sun, X., Li, B., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5014659 · Cited by 80
EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
Wang, Z., & Fang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s69690 · Cited by 80
Corominas-Faja, B., Oliveras‐Ferraros, C., Cuyàs, E., Segura‐Carretero, A., Joven, J., Martı́n-Castillo, B., Barrajón‐Catalán, E., Micol, V., Bosch‐Barrera, J., & Menéndez, J. A. (2013) · Cell Cycle · doi:10.4161/cc.26417 · Cited by 80
Piotrowska, Z., Costa, D. B., Oxnard, G. R., Huberman, M., Gainor, J. F., Lennes, I. T., Muzikansky, A., Shaw, A. T., Azzoli, C. G., Heist, R. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy336 · Cited by 79
Langer, C. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8782 · Cited by 79
Lee, K. H., Lee, J. S., Kim, S., Pereira, J. R., Han, B., Song, X., Wang, J., Kim, H.-K., Sahoo, T. P., Digumarti, R., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.035 · Cited by 79
Lohinai, Z., Hoda, M. A., Fábián, K., Ostoros, G., Rásó, E., Barbai, T., Tı́már, J., Kovalszky, I., Cserepes, M., Rózsás, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000492 · Cited by 79
Shi, Y., Chen, G., Wang, X., Liu, Y., Wu, L., Hao, Y., Liu, C., Zhu, S., Zhang, X., Li, Y., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.07.1143 · Cited by 79
Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy
Jakopović, M., Thomas, A., Balasubramaniam, S., Schrump, D. S., Giaccone, G., & Bates, S. E. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00261 · Cited by 79
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
Zhou, J. R., Wu, Z., Wong, G. S., Pectasides, E., Nagaraja, A. K., Stachler, M. D., Zhang, H., Chen, T., Zhang, H., Liu, J. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms13897 · Cited by 79
NSCLC and HER2: between lights and shadows
Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78
Ishii, H., Azuma, K., Sakai, K., Kawahara, A., Yamada, K., Tokito, T., Okamoto, I., Nishio, K., & Hoshino, T. (2015) · Oncotarget · doi:10.18632/oncotarget.5068 · Cited by 78
Bronte, G., Rolfo, C. D., Giovannetti, E., Cicero, G., Pauwels, P., Passiglia, F., Castiglia, M., Rizzo, S., Vullo, F. L., Fiorentino, E., et al. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.003 · Cited by 78
Self-citationNew Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer
Salama, J. K., & Vokes, E. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5064 · Cited by 78
Smarter drugs emerging in pancreatic cancer therapy
Kleger, A., Perkhofer, L., & Seufferlein, T. T. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu013 · Cited by 78
Imamura, F., Uchida, J., Kukita, Y., Kumagai, T., Nishino, K., Inoue, T., Kimura, M., Oba, S., & Kato, K. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.023 · Cited by 78
Shin, D. H., Lee, D., Hong, D. W., Hong, S. H., Hwang, J.-A., Lee, B. I., You, H. J., Lee, G. K., Kim, I.-H., Lee, Y.-S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11913 · Cited by 78
Hwang, W., Chiu, Y.-F., Kuo, M.-H., Lee, K.-L., Lee, A.-C., Yu, C.-C., Chang, J.-L., Huang, W.-C., Hsiao, S.-H., Lin, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3168 · Cited by 78
Hou, H., Qin, K., Yu, L., Zhang, C., Liu, D., Jiang, H., Liu, K., Zhu, J., Lv, H., Li, T., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s201513 · Cited by 78
Management of egfr tki—Induced Dermatologic Adverse Events
Melosky, B. L., Leighl, N. B., Rothenstein, J. M., Sangha, R. S., Stewart, D. J., & Papp, K. A. (2015) · Current Oncology · doi:10.3747/co.22.2430 · Cited by 78
Ring, B. Z., Hout, D. R., Morris, S. W., Lawrence, K. D., Schweitzer, B. L., Bailey, D. B., Lehmann, B. D., Pietenpol, J. A., & Seitz, R. S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2198-0 · Cited by 78
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals
Kletzl, H., Giraudon, M., Ducray, P. S., Abt, M., Hamilton, M., & Lum, B. L. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000212 · Cited by 78
Chen, Y., Hsieh, M., Wu, S., Chang, Y., Yu, C., Yang, J. C., Yang, P., & Shih, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.022 · Cited by 78
Enewold, L., & Thomas, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156728 · Cited by 78
Boeck, S., Jung, A., Laubender, R. P., Neumann, J., Egg, R., Goritschan, C., Ormanns, S., Haas, M., Modest, D. P., Kirchner, T., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0767-4 · Cited by 77
Roche, J., Nasarre, P., Gemmill, R. M., Baldys, A., Pontis, J., Korch, C. T., Guilhot, J., Ait‐Si‐Ali, S., & Drabkin, H. A. (2013) · Cancers · doi:10.3390/cancers5020334 · Cited by 77
Jiang, T., & Zhou, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.08.02 · Cited by 77
Martínez‐Martí, A., Felip, E., Matito, J., Mereu, E., Navarro, A., Cedrés, S., Pardo, N., de Castro, A. M. M., Remón, J., Miquel, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx396 · Cited by 77
Self-citationOkamoto, I., Morita, S., Tashiro, N., Imamura, F., Inoue, A., Seto, T., Yamamoto, N., Ohe, Y., Nakagawa, K., & Fukuoka, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.005 · Cited by 77
Hedgehog Signaling Pathway and Cancer Therapeutics: Progress to Date
Ruch, J. M., & Kim, E. J.-H. (2013) · Drugs · doi:10.1007/s40265-013-0045-z · Cited by 77
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K. J., Neal, J. W., & Wakelee, H. A. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.12.009 · Cited by 77
Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
Baik, C. S., Chamberlain, M. C., & Chow, L. Q. M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000615 · Cited by 77
Huang, J., Meng, L., Yang, B. L., Sun, S., Luo, Z., & Chen, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-61571-5 · Cited by 77
Emerging technologies for hybridization based single nucleotide polymorphism detection
Knez, K., Spasić, D., Janssen, K. P. F., & Lammertyn, J. (2013) · The Analyst · doi:10.1039/c3an01436c · Cited by 76
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
Saarenheimo, J., Eigėlienė, N., Andersén, H., Tiirola, M., & Jekunen, A. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00129 · Cited by 76
Liquid biopsy tracking of lung tumor evolutions over time
Russo, A., de Miguel‐Pérez, D., Gunasekaran, M., Scilla, K. A., Lapidus, R. S., Cooper, B., Mehra, R., Adamo, V., Malapelle, U., & Rolfo, C. D. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1680287 · Cited by 76
Self-citationCanale, M., Petracci, E., Delmonte, A., Bronte, G., Chiadini, E., Ludovini, V., Dubini, A., Papi, M., Baglivo, S., Luigi, N. D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041047 · Cited by 76
EGFR T790M resistance mutation in non small-cell lung carcinoma
Denis, M. G., Vallée, A., & Théoleyre, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.039 · Cited by 76
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000189 · Cited by 76
The multiple paths towards MET receptor addiction in cancer
Duplaquet, L., Kherrouche, Z., Baldacci, S., Jamme, P., Cortot, A. B., Copin, M., & Tulasne, D. (2018) · Oncogene · doi:10.1038/s41388-018-0185-4 · Cited by 76
Feng, P., Chen, K.-Y., Huang, Y., Luo, C.-S., Wu, S. M., Chen, T.-T., Lee, C.-N., Yeh, C., Chuang, H., Han, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.032 · Cited by 76
Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer
Zhang, Y., Li, M., & Hu, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.061 · Cited by 76
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
Villaflor, V., Won, B., Nagy, R., Banks, K., Lanman, R. B., Talasaz, A., & Salgia, R. (2016) · Oncotarget · doi:10.18632/oncotarget.11801 · Cited by 75
Wang, L., Zhao, H., Xu, Y., Li, J., Deng, C., Deng, Y., Bai, J., Li, X., Xiao, Y., & Zhang, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31865 · Cited by 75
Wei, Z., Yang, X., Ye, X., Feng, Q., Xu, Y., Zhang, L., Sun, W., Dong, Y., Qi, M., Li, T., et al. (2020) · European Radiology · doi:10.1007/s00330-019-06613-x · Cited by 75
Understanding EGFR heterogeneity in lung cancer
Passaro, A., Malapelle, U., Re, M. D., Attili, I., Russo, A., Guerini‐Rocco, E., Fumagalli, C., Pisapia, P., Pepe, F., Luca, C. D., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000919 · Cited by 75
Self-citationA Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors
El–Gamal, M. I., Mewafi, N. H., Abdelmotteleb, N. E., Emara, M. A., Tarazi, H., Sbenati, R. M., Madkour, M. M., Zaraei, S., Shahin, A. I., & Anbar, H. S. (2021) · Molecules · doi:10.3390/molecules26237376 · Cited by 75
Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.
Khoo, C., Rogers, T.-M., FELLOWES, A. P., Bell, A. H., & Fox, S. B. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.01.10 · Cited by 75
Toschi, L., Finocchiaro, G., Nguyen, T. T., Skokan, M. C., Giordano, L., Gianoncelli, L., Perrino, M., Siracusano, L., Tommaso, L. D., Infante, M. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095303 · Cited by 75
Biomarkers in Lung Adenocarcinoma: A Decade of Progress
Sholl, L. M. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0128-ra · Cited by 75
T cell Bim levels reflect responses to anti–PD-1 cancer therapy
Dronca, R. S., Liu, X., Harrington, S. M., Chen, L., Cao, S., Kottschade, L. A., McWilliams, R. R., Block, M. S., Nevala, W. K., Thompson, M. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86014 · Cited by 75
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
Vishwanathan, K., Dickinson, P. A., So, K., Thomas, K., Chen, Y., de Castro, J., Dingemans, A. C., Kim, H. R., Kim, J.-H., Krebs, M., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13534 · Cited by 75
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Le, T., & Gerber, D. E. (2019) · Cancers · doi:10.3390/cancers11030366 · Cited by 75
Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma
Hong, D., Xu, K., Zhang, L., Wan, X., & Guo, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00028 · Cited by 75
Nishino, M., Cardarella, S., Dahlberg, S. E., Jackman, D. M., Ramaiya, N. H., Hatabu, H., Rabin, M. S., Janne, P. A., & Johnson, B. E. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.007 · Cited by 74
Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer
Hagihara, K., Kajimoto, K., Osaga, S., Nagai, N., Shimosegawa, E., Nakata, H., Saito, H., Nakano, M., Takeuchi, M., Kanki, H., et al. (2020) · Nutrients · doi:10.3390/nu12051473 · Cited by 75
Transitioning single-cell genomics into the clinic
Lim, J. W. Y., Chin, V. T., Fairfax, K. A., Moutinho, C., Suan, D., Ji, H. P., & Powell, J. E. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00613-w · Cited by 74
The Management of Brain Metastases in Non-Small Cell Lung Cancer
Owen, S. P., & Souhami, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00248 · Cited by 75
Li, X., Ren, R., Ren, S., Chen, X., Cai, W., Zhou, F., Zhang, Y., Su, C., Zhao, C., Li, J., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.04.006 · Cited by 74
Bria, E., Pilotto, S., Amato, E., Fassan, M., Novello, S., Peretti, U., Vavalà, T., Kinspergher, S., Righi, L., Santo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3727 · Cited by 74
Self-citationS768I Mutation in EGFR in Patients with Lung Cancer
Leventakos, K., Kipp, B. R., Rumilla, K. M., Winters, J. L., Yi, E. S., & Mansfield, A. S. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.007 · Cited by 74
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
Blumenthal, G. M., Kluetz, P. G., Schneider, J., Goldberg, K. B., McKee, A. E., & Pazdur, R. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0152 · Cited by 74
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Kuiper, J. L., Hashemi, S. M. S., Thunnissen, E., Snijders, P. J. F., Grünberg, K., Bloemena, E., Sie, D., Postmus, P. E., Heideman, D. A. M., & Smit, E. F. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.372 · Cited by 73
Melosky, B., & Hirsh, V. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00238 · Cited by 73
Adaptive stress signaling in targeted cancer therapy resistance
Pazarentzos, E., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.26 · Cited by 73
Takahama, T., Sakai, K., Takeda, M., Azuma, K., Hida, T., Hirabayashi, M., Oguri, T., Tanaka, H., Ebi, N., Sawa, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11303 · Cited by 73
Ambroggi, M., Biasini, C., Toscani, I., Orlandi, E., Bertè, R., Mazzari, M., & Cavanna, L. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4184-3 · Cited by 73
Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., & Green, J. A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010383.pub3 · Cited by 73
Zhao, Y., He, Y., Wang, W., Cai, Q., Ge, F., Chen, Z., Zheng, J., Zhang, Y., Deng, H., Chen, Y., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00379-6 · Cited by 76
Berger, L. A., Riesenberg, H., Bokemeyer, C., & Atanackovic, D. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.004 · Cited by 73
Landi, L. M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.846830 · Cited by 73
Cadranel, J. L., Mauguen, A., Beau‐Faller, M., Zalcman, G., Buisine, M., Westeel, V., Longchampt, É., Wislez, M., Coudert, B. P., Daniel, C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318265b2b5 · Cited by 73
Drug-biomarker co-development in oncology – 20 years and counting
Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 75
MEK inhibitors under development for treatment of non-small-cell lung cancer
Kim, C. G., & Giaccone, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1415324 · Cited by 73
Sanada, H., Seki, N., Mizuno, K., Misono, S., Uchida, A., Yamada, Y., Moriya, S., Kikkawa, N., Machida, K., Kumamoto, T., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184482 · Cited by 73
Bai, X., Zhang, X., Yang, S., An, S., Chen, Z., Su, J., Xie, Z., Gou, L.-Y., & Wu, Y.-L. L. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149370 · Cited by 72
Yang, J., Fang, J., Shu, Y., Chang, J., Chen, G., He, J., Li, W., Liu, X., Yang, N., Zhou, C., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-01010-4 · Cited by 72
EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
Choi, H.-J., Jeong, Y. J., Kim, J., & Hoe, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1238639 · Cited by 72
Ferro, A., Marinato, G. M., Mulargiu, C., Marino, M., Pasello, G., Guarneri, V., & Bonanno, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104295 · Cited by 72
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh, V. (2015) · BioDrugs · doi:10.1007/s40259-015-0130-9 · Cited by 72
Gao, X. Y., Le, X., & Costa, D. B. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162103 · Cited by 72
Dorantes-Heredia, R., Ruiz-Morales, J. M., & Cano-García, F. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.10 · Cited by 73
Tomasini, P., Serdjebi, C., Khobta, N., Métellus, P., Ouafik, L., Nanni, I., Greillier, L., Loundou, A., Fina, F., Mascaux, C., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122132 · Cited by 72
Kim, S. T., Banks, K. C., Lee, S., Kim, K., Park, J. O., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Lanman, R. B., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00059 · Cited by 72
Costa, D. B. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.04 · Cited by 71
Ellis, P. M., Coakley, N., Feld, R. D., Kuruvilla, S., & Ung, Y. (2015) · Current Oncology · doi:10.3747/co.22.2566 · Cited by 71
Liquid Biopsy to Identify Actionable Genomic Alterations
Ou, S. I., Nagasaka, M., & Zhu, V. W. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199765 · Cited by 71
Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity
Gupta, P., Makkar, T. K., Goel, L., & Pahuja, M. (2022) · Immunologic Research · doi:10.1007/s12026-022-09307-7 · Cited by 71
Gou, L.-Y., Niu, F., Wu, Y.-L. L. C., & Zhong, W. (2015) · Cancer · doi:10.1002/cncr.29531 · Cited by 71
Organoid development in cancer genome discovery
Gao, D., & Chen, Y. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.02.007 · Cited by 71
Personalized Targeted Therapy for Lung Cancer
Wu, K., House, L. K., Liu, W., & Cho, W. C. S. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911471 · Cited by 71
Prognostic and predictive factors for lung cancer
Paesmans, M. (2012) · Breathe · doi:10.1183/20734735.006911 · Cited by 71
Patil, V., Noronha, V., Joshi, A., Choughule, A. B., Bhattacharjee, A., Kumar, R., Goud, S., More, S. B., Ramaswamy, A., Karpe, A. P., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000168 · Cited by 71
Lin, M., Su, K., Su, T.-J., Chang, C., Lin, J., Lee, Y., Yu, S., Chen, J., & Hsieh, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.006 · Cited by 70
Metadata
- Authors
- Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M. A., Terrasa, J., Muñoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J. L., Sanchez, J. J., Molina, M. A., Taron, M., & Paz-Ares, L.
- Affiliations
- Institut Català d'Oncologia (ES)
- Centre François Baclesse (FR)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Policlinico Umberto I (IT)
- Hospital Clínico Universitario de Valencia (ES)
- Hôpital Pontchaillou (FR)
- Hospital Son Llatzer (ES)
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" (IT)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Hospital Universitario Son Dureta (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Clínico Universitario Lozano Blesa (ES)
- Centre Hospitalier du Mans (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- La Maddalena (IT)
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Centre Hospitalier de Mulhouse (FR)
- Centro di Riferimento Oncologico (IT)
- Hospital Universitario Miguel Servet (ES)
- Sapienza University of Rome (IT)
- Clinica Rotger (ES)
- Pivotal (Spain) (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Corresponding author
- Rosell, Rafael
- ORCID
- Rosell, Rafael
- Carcereny, Enric
- Gervais, Radj
- Felip, Enriqueta
- Cobo, Manuel
- Garrido, Pilar
- Longo, Flavia
- Insa, Amelia
- Corre, Romain
- Altavilla, Giuseppe
- Provencio, Mariano
- Valdivia, Javier
- Isla, Dolores
- Molinier, Olivier
- Gebbia, Vittorio
- Bearz, Alessandra
- Artal, Angel
- Cortesi, Enrico
- Rolfo, Christian
- Queralt, Cristina
- Paz-Ares, Luis
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 13
- Issue
- 3
- Pages
- 239-246
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2111662961
- Cited by
- 5,489
- References
- 23
- Citations by year
- 2026: 92 · 2025: 169 · 2024: 216 · 2023: 269 · 2022: 367 · 2021: 422 · 2020: 441 · 2019: 440 · 2018: 498 · 2017: 534 · 2016: 509 · 2015: 537 · 2014: 448 · 2013: 401 · 2012: 138
- FWCI
- 392.78
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- erlotinib, EGFR-mutant non-small cell lung cancer, first-line therapy, exon 19 deletion, L858R mutation, cisplatin, docetaxel, gemcitabine, carboplatin, progression-free survival, targeted therapy, European patients, drug safety, adverse events, treatment discontinuation, EGFR tyrosine kinase inhibitors
- MeSH terms
- Erlotinib Hydrochloride, Docetaxel, Gemcitabine, Administration, Oral, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Drug Administration Schedule, Europe, Exons, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prospective Studies, Quinazolines, Time Factors, Chi-Square Distribution, Proportional Hazards Models, Carboplatin, Treatment Outcome, Disease-Free Survival, Patient Selection, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Precision Medicine, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
